KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Total Liabilities (2016 - 2025)

Gsk (GSK) has 9 years of Total Liabilities data on record, last reported at -$17.5 billion in Q4 2024.

  • For Q4 2024, Total Liabilities fell 5.92% year-over-year to -$17.5 billion; the TTM value through Dec 2024 reached -$17.5 billion, down 5.92%, while the annual FY2024 figure was -$17.5 billion, 5.26% down from the prior year.
  • Total Liabilities reached -$17.5 billion in Q4 2024 per GSK's latest filing, down from -$16.6 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $78.7 billion in Q4 2020 and bottomed at -$20.3 billion in Q4 2021.
  • Average Total Liabilities over 5 years is $2.4 billion, with a median of -$16.6 billion recorded in 2023.
  • Peak YoY movement for Total Liabilities: surged 636.9% in 2020, then plummeted 125.78% in 2021.
  • A 5-year view of Total Liabilities shows it stood at $78.7 billion in 2020, then tumbled by 125.78% to -$20.3 billion in 2021, then surged by 38.75% to -$12.4 billion in 2022, then tumbled by 33.26% to -$16.6 billion in 2023, then decreased by 5.92% to -$17.5 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were -$17.5 billion in Q4 2024, -$16.6 billion in Q4 2023, and -$12.4 billion in Q4 2022.